- Home
- CRBU vs PAVS Comparison
CRBU vs PAVS Comparison
Compare CRBU & PAVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRBU
- PAVS
- Stock Information
- Founded
- CRBU 2011
- PAVS 2004
- Country
- CRBU United States
- PAVS United States
- Employees
- CRBU N/A
- PAVS N/A
- Industry
- CRBU Medicinal Chemicals and Botanical Products
- PAVS Medicinal Chemicals and Botanical Products
- Sector
- CRBU Health Care
- PAVS Health Care
- Exchange
- CRBU Nasdaq
- PAVS Nasdaq
- Market Cap
- CRBU 93.0M
- PAVS 89.6M
- IPO Year
- CRBU 2021
- PAVS 2019
- Fundamental
- Price
- CRBU $0.74
- PAVS $1.33
- Analyst Decision
- CRBU Strong Buy
- PAVS
- Analyst Count
- CRBU 5
- PAVS 0
- Target Price
- CRBU $11.80
- PAVS N/A
- AVG Volume (30 Days)
- CRBU 1.1M
- PAVS 6.8K
- Earning Date
- CRBU 05-06-2025
- PAVS 01-01-0001
- Dividend Yield
- CRBU N/A
- PAVS N/A
- EPS Growth
- CRBU N/A
- PAVS N/A
- EPS
- CRBU N/A
- PAVS N/A
- Revenue
- CRBU $9,994,000.00
- PAVS $6,544,819.00
- Revenue This Year
- CRBU N/A
- PAVS N/A
- Revenue Next Year
- CRBU $163.34
- PAVS N/A
- P/E Ratio
- CRBU N/A
- PAVS N/A
- Revenue Growth
- CRBU N/A
- PAVS N/A
- 52 Week Low
- CRBU $0.66
- PAVS $0.32
- 52 Week High
- CRBU $4.21
- PAVS $1.50
- Technical
- Relative Strength Index (RSI)
- CRBU 34.01
- PAVS 43.14
- Support Level
- CRBU $0.71
- PAVS $1.29
- Resistance Level
- CRBU $0.94
- PAVS $1.40
- Average True Range (ATR)
- CRBU 0.10
- PAVS 0.05
- MACD
- CRBU 0.00
- PAVS -0.00
- Stochastic Oscillator
- CRBU 23.44
- PAVS 66.67
About CRBU Caribou Biosciences Inc.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.
About PAVS Paranovus Entertainment Technology Ltd.
Paranovus Entertainment Technology Ltd through its subsidiary, is engaged in the AI-powered entertainment industry, aiming to provide users with AI-driven games and applications to deliver immersive and engaging entertainment experiences. It is planning to launch SimTwin application which will allow users to interact with digital versions of people and capture life moments. The company also has a software development agreement with Blueline Studios Inc which is developing 10,000 Lives, a mobile game where players pursue various careers and life goals using a board game mechanic.